Day: February 4, 2015

FDA To Review CSL Behring's New Long-Lasting Hemophilia B Product

CSL Behring announced that the U.S. Food and Drug Administration (FDA) has accepted for review its Biologics License Application (BLA) for the marketing authorization of its long-acting fusion protein linking recombinant coagulation factor IX with recombinant albumin (rIX-FP). Upon FDA approval, rIX-FP will provide hemophilia B patients with a long-acting treatment option with dosing intervals up […]

Infusing Love: Discipline, Divorce, & Dating

Oh February, the month of love for those who have someone, or the month of single awareness for those who don’t.  I fall into the single category. I’ve been reevaluating some things as to why I am single; reviewing the lessons I’ve learned of being a single mom of a child with hemophilia.I’m 45 years […]

FDA Accepts CSL Behring's Application for New Long-Acting Hemophilia B Product

This is an edited version of a press release from CSL Behring. To read the full release, please click here. ____________________  CSL Behring announced that the U.S. Food and Drug Administration (FDA) has accepted for review its Biologics License Application (BLA) for the marketing authorization of its long-acting fusion protein linking recombinant coagulation factor IX with recombinant […]